Indication
For treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy
Medicine details
- Medicine name:
- tofacitinib (Xeljenz)
- SMC ID:
- SMC2463
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Publication due date:
- 12 September 2022
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 04 July 2022